GDF3 promotes adipose tissue macrophage-mediated inflammation via altered chromatin accessibility during aging

In Hwa Jang1,2,3, Anna Carey2,3,4, Victor Kruglov2

  • 1Biochemistry, Molecular Biology, and Biophysics Graduate Program, Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.

Nature Aging
|December 15, 2025
PubMed

Insights

Aging increases inflammation and macrophage susceptibility to endotoxemia. This study reveals that GDF3-SMAD2/3 signaling drives this age-related inflammation, offering a potential therapeutic target.

Area of Science:

  • Immunology
  • Gerontology
  • Molecular Biology

Background:

  • Aging is associated with increased systemic inflammation and heightened susceptibility to infections like endotoxemia.
  • Proinflammatory macrophages contribute significantly to age-related inflammatory conditions.

Purpose of the Study:

  • To elucidate the mechanism by which macrophages maintain an inflammatory phenotype during aging.
  • To investigate the role of Growth Differentiation Factor 3 (GDF3) and its signaling pathway in age-associated inflammation and endotoxemia.

Main Methods:

  • Analysis of adipose tissue macrophages from aging mice and human participants.
  • Genetic manipulation (Gdf3 deletion) and pharmacological inhibition of the GDF3-SMAD2/3 pathway.
  • Single-cell RNA sequencing and ATAC-seq to study chromatin remodeling.
  • Validation in a large human cohort (Atherosclerosis Risk in Communities study).

Main Results:

  • An age-dependent increase in GDF3 was observed in adipose tissue macrophages.
  • Deletion of Gdf3 reduced endotoxic inflammation and improved survival in aged mice.
  • Modulation of the GDF3-SMAD2/3 axis regulated macrophage phenotype and endotoxemia lethality.
  • GDF3 was shown to promote an inflammatory state by reducing methylation-dependent chromatin compaction.
  • Human data confirmed the relevance of GDF3 in aging.

Conclusions:

  • The GDF3-SMAD2/3 signaling axis is a key driver of age-associated inflammation by influencing macrophage phenotype and chromatin structure.
  • Targeting the GDF3-SMAD2/3 pathway represents a promising therapeutic strategy for mitigating age-related inflammation and improving outcomes in conditions like endotoxemia.